About Trianni
Trianni is a Healthcare company based in San Francisco (United States) founded in 2010, and was acquired by AbCellera in November 2020. Transgenic mouse platform is utilized for fully human antibody discovery. Its chief executive, as recorded, is Matthias Wabl. Trianni offers products and services including Antibody Discovery Platform. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Life Sciences. Its legal entity is AbCellera Biologics Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Trianni was founded in 2010 in San Francisco, United States, within the biotechnology sector focused on antibody discovery. A next-generation transgenic mouse platform is provided by the company for the isolation of fully human monoclonal antibodies. This technology is made available to pharmaceutical and biotech firms through flexible business agreements tailored to specific project requirements. Operations center on enabling simpler access to high-quality human antibody genes for therapeutic development.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website trianni.com
- Social LinkedIn X
- Acquired by AbCellera (Nov 2020)
- Legal Name Abcellera Biologics Inc.
- Investors
- Acquired byAbCellera
(Nov 2020)
Products & Services of Trianni
Trianni offers a comprehensive portfolio of products and services, including Antibody Discovery Platform.
Platform for discovering antibody-based therapies for medical applications
Investors in Trianni
Trianni has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Abcellera Biologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An AI-enabled platform is used for antibody discovery. | 2012 | abcellera.com | Vancouver, Canada |
Investor details for Trianni
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Trianni
1 people are tracked at Trianni (1 in leadership).
| Name | Role | Group |
|---|---|---|
Matthias Wabl | Chairman & CEO | Leadership |
Complete people profiles for Trianni
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Trianni
2 dated milestones of Trianni across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Trianni is founded.
- Exit Acquired by AbCellera.
Competitors of Trianni
Trianni has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Trianni
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Trianni (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Trianni
Complete news archive for Trianni
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trianni
Trianni was founded in 2010.
Trianni is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Matthias Wabl is the CEO of Trianni, as recorded in our data.
Trianni was founded in 2010 in San Francisco, United States, within the biotechnology sector focused on antibody discovery. A next-generation transgenic mouse platform is provided by the company for the isolation of fully human monoclonal antibodies. This technology is made available to pharmaceutical and biotech firms through flexible business agreements tailored to specific project requirements. Operations center on enabling simpler access to high-quality human antibody genes for therapeutic development.
Trianni's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Trianni offers Antibody Discovery Platform.
Trianni has 1 investor. Key investors include Abcellera Biologics.
Trianni operates through Abcellera Biologics Inc..
Yes. Trianni was acquired by AbCellera in November 2020.